Cytek Biosciences (CTKB) Total Liabilities (2020 - 2026)

Cytek Biosciences has reported Total Liabilities for 7 years, with the latest figure at $121.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 17.96% year-over-year to $121.5 million; the trailing twelve-month figure through Mar 2026 stood at $121.5 million (up 17.96% YoY), and the FY2025 full-year result was $119.8 million, up 15.46% from the prior year.
• Total Liabilities for Q1 2026 stood at $121.5 million, up from $119.8 million in the prior quarter.
• The five-year high for Total Liabilities was $121.5 million in Q1 2026, with the low at $78.4 million in Q1 2022.
• Historically, Total Liabilities has averaged $101.4 million across 5 years, with a median of $101.4 million in 2023.
• Annual changes were most pronounced in 2022 — Total Liabilities surged 7943.7% — and 2024, when it decreased 6.22%.
• Cytek Biosciences' Total Liabilities stood at $93.9 million in 2022, then rose by 7.95% to $101.4 million in 2023, then advanced by 2.34% to $103.8 million in 2024, then grew by 15.46% to $119.8 million in 2025, then climbed by 1.39% to $121.5 million in 2026.
• The last three Total Liabilities figures came in at $121.5 million (Q1 2026), $119.8 million (Q4 2025), and $116.3 million (Q3 2025), per Business Quant data.